<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The exact pathophysiological mechanisms responsible for <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) remain unclear </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have shown that mucosal immune and <z:mp ids='MP_0001845'>inflammatory responses</z:mp>, characterized by specific cytokine and chemokine profiles, may underlie the diverse esophageal phenotypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Interleukin 8 (IL-8), a representative chemokine, mediates neutrophil trafficking via its receptors, mainly CXCR-1 </plain></SENT>
<SENT sid="3" pm="."><plain>The IL-8 mRNA and protein levels are increased in the esophageal mucosa, not only in reflux <z:hpo ids='HP_0100633'>esophagitis</z:hpo> (RE), but also in endoscopy-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> (NERD), through activation of nuclear factor-kappaB (NF-kappaB), which is a pivotal transcription factor </plain></SENT>
<SENT sid="4" pm="."><plain>Mucosal IL-8 concentrations have been found to parallel the endoscopic severity of RE, implying that this cytokine is a key player in the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The mucosal levels of the C-C chemokines, macrophage chemoattractant protein 1 (<z:chebi fb="17" ids="50099">MCP</z:chebi>-1) and regulated on activation <z:mpath ids='MPATH_458'>normal</z:mpath> T-cell-expressed and presumably secreted (RANTES), which primarily attract monocytes and lymphocytes to the site of <z:mp ids='MP_0001845'>inflammation</z:mp>, respectively, are also elevated in RE </plain></SENT>
<SENT sid="6" pm="."><plain>The secreted levels of IL-8 and IL-1beta, a prototype of proinflammatory cytokine, are maximal at the proximal segment within <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> (BE) tissue </plain></SENT>
<SENT sid="7" pm="."><plain>The expression of the two pleiotrophic proinflammatory cytokines, IL-6 and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha, is enhanced in the intestinal epithelium of BE, which places this epithelium at a higher risk for developing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>BE is characterized by a distinct Th-2 predominant cytokine profile (IL-4 and -10), compared to the proinflammatory nature of RE (interferone-gamma) </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment with a <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi>, <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> reduces the mucosal levels of IL-8 mRNA and protein in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, including RE and NERD </plain></SENT>
<SENT sid="10" pm="."><plain>This may occur in part through an anti-inflammatory action of <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> beyond gastric acid inhibition </plain></SENT>
</text></document>